Online citations, reference lists, and bibliographies.
← Back to Search

Combination Of Prostate-specific Antigen, Clinical Stage, And Gleason Score To Predict Pathological Stage Of Localized Prostate Cancer. A Multi-institutional Update.

A. Partin, M. Kattan, E. N. Subong, P. Walsh, K. Wojno, J. Oesterling, P. Scardino, J. Pearson
Published 1997 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
OBJECTIVE To combine the clinical data from 3 academic institutions that serve as centers of excellence for the surgical treatment of clinically localized prostate cancer and develop a multi-institutional model combining serum prostate-specific antigen (PSA) level, clinical stage, and Gleason score to predict pathological stage for men with clinically localized prostate cancer. DESIGN In this update, we have combined clinical and pathological data for a group of 4133 men treated by several surgeons from 3 major academic urologic centers within the United States. Multinomial log-linear regression was performed for the simultaneous prediction of organ-confined disease, isolated capsular penetration, seminal vesicle involvement, or pelvic lymph node involvement. Bootstrap estimates of the predicted probabilities were used to develop nomograms to predict pathological stage. Additional bootstrap analyses were then obtained to validate the performance of the nomograms. PATIENTS AND SETTINGS A total of 4133 men who had undergone radical retropubic prostatectomy for clinically localized prostate cancer at The Johns Hopkins Hospital (n=3116), Baylor College of Medicine (n=782), and the University of Michigan School of Medicine (n=235) were enrolled into this study. None of the patients had received preoperative hormonal or radiation therapy. OUTCOME MEASURES Simultaneous prediction of organ-confined disease, isolated capsular penetration, seminal vesicle involvement, or pelvic lymph node involvement using updated nomograms. RESULTS Prostate-specific antigen level, TNM clinical stage, and Gleason score contributed significantly to the prediction of pathological stage (P<.001). Bootstrap estimates of the median and 95% confidence interval of the predicted probabilities are presented in the nomograms. For most cells in the nomograms, there is a greater than 25% probability of qualifying for more than one of the pathological stages. In the validation analyses, 72.4% of the time the nomograms correctly predicted the probability of a pathological stage to within 10% (organ-confined disease, 67.3%; isolated capsular penetration, 59.6%; seminal vesicle involvement, 79.6%; pelvic lymph node involvement, 82.9%). CONCLUSIONS The data represent a multi-institutional modeling and validation of the clinical utility of combining PSA level measurement, clinical stage, and Gleason score to predict pathological stage for a group of men with localized prostate cancer. Clinicians can use these nomograms when counseling individual patients regarding the probability of their tumor being a specific pathological stage; this will enable patients and physicians to make more informed treatment decisions based on the probability of a pathological stage, as well as risk tolerance and the values they place on various potential outcomes.
This paper references
10.1001/JAMA.1993.03510080052031
Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening.
W. J. Catalona (1993)
10.1016/S0094-0143(05)70386-4
Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control.
C. Pound (1997)
10.1016/S0022-5347(17)43003-5
Correlation of clinical stage, serum prostatic acid phosphatase and preoperative Gleason grade with final pathological stage in 275 patients with clinically localized adenocarcinoma of the prostate.
J. Oesterling (1987)
10.1016/S0090-4295(99)80195-2
The role of transrectal ultrasound-guided biopsy-based staging, preoperative serum prostate-specific antigen, and biopsy Gleason score in prediction of final pathologic diagnosis in prostate cancer.
Perinchery Narayan (1995)
10.1002/(SICI)1097-0142(19970201)79:3<528::AID-CNCR15>3.0.CO;2-5
Evaluation of a Nomogram used to predict the pathologic stage of clinically localized prostate carcinoma
M. Kattan (1997)
10.1016/S0090-4295(94)80050-2
Utility of preoperative serumprostate-specific antigen concentration and biopsy Gleason score in predicting risk of pelvic lymph node metastases in prostate cancer
Perinchery Narayan (1994)
10.1016/S0022-5347(17)35303-X
Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: the influence of prostate specific antigen cancer density.
K. Blackwell (1994)
10.1016/S0022-5347(17)35912-8
Analysis of risk factors associated with prostate cancer extension to the surgical margin and pelvic node metastasis at radical prostatectomy.
D. A. Ackerman (1993)
10.3322/CANJCLIN.46.1.5
Cancer statistics, 1996
S. Parker (1996)
NCCN Prostate Cancer Practice Guidelines. The National Comprehensive Cancer Network.
L. Baker (1996)
10.1080/00401706.1991.10484817
Categorical Data Analysis
A. Agresti (1991)
10.1016/S0022-5347(17)35410-1
The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer.
A. Partin (1993)
10.1016/S0022-5347(17)35239-4
Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer.
D. L. Bluestein (1994)
10.1016/0360-3016(94)90138-4
Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer.
M. Roach (1994)
10.1016/S0022-5347(01)65590-3
An algorithm for predicting nonorgan confined prostate cancer using the results obtained from sextant core biopsies with prostate specific antigen level.
R. Badalament (1996)
10.1016/0090-4295(93)90558-R
Ability of preoperative serum prostate-specific antigen value to predict pathologic stage and DNA ploidy. Influence of clinical stage and tumor grade.
E. Kleer (1993)
10.1016/S0022-5347(17)38574-9
Cancer control following anatomical radical prostatectomy: an interim report.
R. A. Morton (1991)
10.1016/S0022-5347(17)42630-9
Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy.
J. Oesterling (1988)
10.1046/J.1464-410X.1996.00117.X
The role of digital rectal examination, biopsy Gleason sum and prostate-specific antigen in selecting patients who require pelvic lymph node dissections for prostate cancer.
E. Rogers (1996)
10.2307/2348146
An introduction to the bootstrap
B. Efron (1993)
Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years.
A. Partin (1993)
10.1016/S0090-4295(94)80134-7
Serum prostate-specific antigen, clinical stage, pathologic grade, and the incidence of nodal metastases in prostate cancer.
M. Sands (1994)
10.1016/S0022-5347(01)66267-0
Prediction of capsular perforation and seminal vesicle invasion in prostate cancer.
D. Bostwick (1996)



This paper is referenced by
10.1016/S1078-1439(02)00203-X
Predictors of extracapsular extension and positive margins in African American and white men.
E. Paquette (2003)
10.1111/j.1464-410X.2009.09161.x
Extended vs standard pelvic lymphadenectomy during laparoscopic radical prostatectomy for intermediate‐ and high‐risk prostate cancer
C. Eden (2010)
10.11182/JASTRO1989.14.79
PATTERNS OF CARE STUDY AND EVIDENCE BASED MEDICINE FOR RADIATION THERAPY
K. Nakamura (2002)
10.1038/sj.pcan.4500612
Avoidance and management of positive surgical margins before, during and after radical prostatectomy
S. Bott (2002)
10.1590/S1677-55382004000400004
Biochemical failure as single abnormality in patients with prostate cancer following radical treatment with external radiotherapy: follow-up without immediate treatment.
S. Faria (2004)
10.1016/S0090-4295(01)01486-8
Influence of biopsy perineural invasion on long-term biochemical disease-free survival after radical prostatectomy.
K. O'malley (2002)
10.1159/000020282
Is One Set of Sextant Biopsies Enough to Rule Out Prostate Cancer? Influence of Transition and Total Prostate Volumes on Prostate Cancer Yield
B. Djavan (2000)
10.1097/01.JU.0000062548.28015.F6
An artificial neural network for prostate cancer staging when serum prostate specific antigen is 10 ng./ml. or less.
A. Zlotta (2003)
10.1038/ncpuro0971
Permanent prostate seed brachytherapy: a current perspective on the evolution of the technique and its application
A. Sahgal (2007)
10.1097/SPC.0b013e3282f125ec
Predicting outcomes in patients with urologic cancers
P. Karakiewicz (2007)
10.1016/j.transproceed.2009.01.111
Is localized prostate cancer an obstacle for an immediate consideration for renal transplantation? A case report.
Burak Kocak (2009)
10.1200/JCO.2005.03.5311
Early versus delayed androgen deprivation for prostate cancer: new fuel for an old debate.
C. Ryan (2005)
10.1016/J.RADONC.2007.01.014
Tumour and target volumes in permanent prostate brachytherapy: a supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy.
C. Salembier (2007)
10.1016/J.CDP.2006.04.007
The value of digital rectal examination as a predictor of prostate cancer diagnosis among United States Veterans referred for prostate biopsy.
M. Issa (2006)
10.3816/CGC.2004.N.003
Biochemical recurrence and survival prediction models for the management of clinically localized prostate cancer.
A. Tewari (2004)
10.3816/CGC.2003.N.015
Population screening for prostate cancer and emerging concepts for young men.
J. Moul (2003)
DEVELOPMENT OF NOVEL ASSAYS FOR MEASURING DIFFERENT MOLECULAR FORMS OF PROSTATE SPECIFIC ANTIGEN
Ulf-Håkan Stenman (2009)
10.1007/s13193-017-0671-0
Preoperative Predictors of Extraprostatic Extension of Prostate Cancer (pT3a) in a Contemporary Indian Cohort
S. Arora (2017)
10.1038/pcan.2013.15
Analysis of the correlation between endorectal MRI response to neoadjuvant chemotherapy and biochemical recurrence in patients with high-risk localized prostate cancer
M. Galsky (2013)
10.1016/S2007-4085(15)30029-X
Correlación entre número de cilindros positivos y enfermedad extraprostática en pacientes operados de prostatectomía radical
G. Hernández-Palacios (2014)
10.1002/(SICI)1096-9098(199811)69:3<156::AID-JSO7>3.0.CO;2-D
Quality of life in patients undergoing salvage procedures for locally recurrent prostate cancer
M. Tefilli (1998)
10.1016/S0167-8140(00)00291-7
High dose rate prostate brachytherapy: the California Endocurietherapy (CET) method.
D. Demanes (2000)
10.1016/S1278-3218(01)00126-3
Cancers de la prostate
P. Bey (2001)
Original article Predictors of extracapsular extension and positive margins in African American and White men
E. Paquette (2003)
10.1007/s00345-009-0419-8
Oncologic outcome after radical prostatectomy in men with PSA values above 20 ng/ml: a monocentric experience
Kien Nguyen (2009)
10.1201/B14401-3
Radical Perineal Prostatectomy in the Management of Localized Prostate Cancer
A. Feng (2004)
Vergleich des Differenzierungsgrades (Gleason-Score) beim Prostatakarzinom zwischen präoperativer Biopsie und Prostatektomiepräparat
A. Kohler (2014)
Prädiktoren eines positiven Schnittrandes und dessen Auswirkung auf die onkologischen Langzeitergebnisse nach transperitonealer radikaler laparoskopischer Prostatektomie retrospektive Studie bei über 1.800 Patienten in den Jahren 1999 - 2007 an der Klinik für Urologie der Charité
Universitätsmedizin Berlin (2015)
[Concordance between Gleason scores of trans rectal biopsies and the surgical piece of radical prostatectomy].
Óscar Tapia (2011)
10.1093/jjco/hyr030
Biochemical recurrence after radical prostatectomy with or without pelvic lymphadenectomy in Korean men with high-risk prostate cancer.
J. Ku (2011)
10.1590/s1679-45082010ao1592
Análise comparativa das técnicas de prostatectomia radical perineal e suprapúbica na abordagem do câncer de próstata localizado
Gelbert Luiz Chamon do Carmo Amorim (2010)
10.1016/s1569-9056(18)31754-8
Pelvic lymph node metastases in prostate cancer: Preoperative detection with dynamic contrast-enhanced magnetic resonance imaging compared with postoperative pathologic result of pelvic lymph node dissection
J. H. Hwang (2018)
See more
Semantic Scholar Logo Some data provided by SemanticScholar